Hims & Hers Health (NYSE:HIMS), a direct-to-consumer digital health platform focusing on telehealth, subscription medications, and personalized care, released its second quarter 2 ...

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming ...

SAN FRANCISCO, CA — Hims & Hers Health, Inc. (NYSE: HIMS) found itself at a familiar crossroads following its Q2 2025 ...

Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

In June, Novo Nordisk ( NVO) ended a brief partnership that allowed Hims & Hers members to access its weight loss drug, Wegovy. The termination was due to concerns that the company was violating ...

Shares of Hims & Hers Health fell 10% in afterhours trading on Monday after the telehealth company reported second-quarter ...

We came across a bullish thesis on Hims & Hers Health, Inc. on The Musings of Ozz’s substack by Christopher De Ozz. In this ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...